Literature DB >> 26565029

Synthetic Antibodies Inhibit Bcl-2-associated X Protein (BAX) through Blockade of the N-terminal Activation Site.

Onyinyechukwu Uchime1, Zhou Dai2, Nikolaos Biris1, David Lee3, Sachdev S Sidhu4, Sheng Li3, Jonathan R Lai5, Evripidis Gavathiotis6.   

Abstract

The BCL-2 protein family plays a critical role in regulating cellular commitment to mitochondrial apoptosis. Pro-apoptotic Bcl-2-associated X protein (BAX) is an executioner protein of the BCL-2 family that represents the gateway to mitochondrial apoptosis. Following cellular stresses that induce apoptosis, cytosolic BAX is activated and translocates to the mitochondria, where it inserts into the mitochondrial outer membrane to form a toxic pore. How the BAX activation pathway proceeds and how this may be inhibited is not yet completely understood. Here we describe synthetic antibody fragments (Fabs) as structural and biochemical probes to investigate the potential mechanisms of BAX regulation. These synthetic Fabs bind with high affinity to BAX and inhibit its activation by the BH3-only protein tBID (truncated Bcl2 interacting protein) in assays using liposomal membranes. Inhibition of BAX by a representative Fab, 3G11, prevented mitochondrial translocation of BAX and BAX-mediated cytochrome c release. Using NMR and hydrogen-deuterium exchange mass spectrometry, we showed that 3G11 forms a stoichiometric and stable complex without inducing a significant conformational change on monomeric and inactive BAX. We identified that the Fab-binding site on BAX involves residues of helices α1/α6 and the α1-α2 loop. Therefore, the inhibitory binding surface of 3G11 overlaps with the N-terminal activation site of BAX, suggesting a novel mechanism of BAX inhibition through direct binding to the BAX N-terminal activation site. The synthetic Fabs reported here reveal, as probes, novel mechanistic insights into BAX inhibition and provide a blueprint for developing inhibitors of BAX activation.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  B cell lymphoma 2 (Bcl-2) family; BAX; antibody engineering; mitochondrial apoptosis; phage display; protein structure; protein targeting; structure-function; synthetic antibody

Mesh:

Substances:

Year:  2015        PMID: 26565029      PMCID: PMC4697190          DOI: 10.1074/jbc.M115.680918

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  The HADDOCK web server for data-driven biomolecular docking.

Authors:  Sjoerd J de Vries; Marc van Dijk; Alexandre M J J Bonvin
Journal:  Nat Protoc       Date:  2010-04-15       Impact factor: 13.491

2.  Bcl-2 and Bax interact via the BH1-3 groove-BH3 motif interface and a novel interface involving the BH4 motif.

Authors:  Jingzhen Ding; Zhi Zhang; G Jane Roberts; Mina Falcone; Yiwei Miao; Yuanlong Shao; Xuejun C Zhang; David W Andrews; Jialing Lin
Journal:  J Biol Chem       Date:  2010-06-28       Impact factor: 5.157

3.  BH3-triggered structural reorganization drives the activation of proapoptotic BAX.

Authors:  Evripidis Gavathiotis; Denis E Reyna; Marguerite L Davis; Gregory H Bird; Loren D Walensky
Journal:  Mol Cell       Date:  2010-11-12       Impact factor: 17.970

Review 4.  The BCL-2 protein family: opposing activities that mediate cell death.

Authors:  Richard J Youle; Andreas Strasser
Journal:  Nat Rev Mol Cell Biol       Date:  2008-01       Impact factor: 94.444

5.  High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries.

Authors:  Frederic A Fellouse; Kaori Esaki; Sara Birtalan; Demetrios Raptis; Vincenzo J Cancasci; Akiko Koide; Parkash Jhurani; Mark Vasser; Christian Wiesmann; Anthony A Kossiakoff; Shohei Koide; Sachdev S Sidhu
Journal:  J Mol Biol       Date:  2007-08-19       Impact factor: 5.469

6.  Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax.

Authors:  Jonathan F Lovell; Lieven P Billen; Scott Bindner; Aisha Shamas-Din; Cecile Fradin; Brian Leber; David W Andrews
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

7.  Two-state selection of conformation-specific antibodies.

Authors:  Junjun Gao; Sachdev S Sidhu; James A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-10       Impact factor: 11.205

Review 8.  The BCL-2 family reunion.

Authors:  Jerry E Chipuk; Tudor Moldoveanu; Fabien Llambi; Melissa J Parsons; Douglas R Green
Journal:  Mol Cell       Date:  2010-02-12       Impact factor: 17.970

9.  Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis.

Authors:  Hyungjin Kim; Ho-Chou Tu; Decheng Ren; Osamu Takeuchi; John R Jeffers; Gerard P Zambetti; James J-D Hsieh; Emily H-Y Cheng
Journal:  Mol Cell       Date:  2009-11-13       Impact factor: 17.970

10.  BAX activation is initiated at a novel interaction site.

Authors:  Evripidis Gavathiotis; Motoshi Suzuki; Marguerite L Davis; Kenneth Pitter; Gregory H Bird; Samuel G Katz; Ho-Chou Tu; Hyungjin Kim; Emily H-Y Cheng; Nico Tjandra; Loren D Walensky
Journal:  Nature       Date:  2008-10-23       Impact factor: 49.962

View more
  15 in total

1.  Isolation of Synthetic Antibodies Against BCL-2-Associated X Protein (BAX).

Authors:  Zhou Dai; Jonathan R Lai
Journal:  Methods Mol Biol       Date:  2019

Review 2.  Progress in targeting the BCL-2 family of proteins.

Authors:  Thomas P Garner; Andrea Lopez; Denis E Reyna; Adam Z Spitz; Evripidis Gavathiotis
Journal:  Curr Opin Chem Biol       Date:  2017-08-17       Impact factor: 8.822

Review 3.  Pharmacological inhibition of Bax-induced cell death: Bax-inhibiting peptides and small compounds inhibiting Bax.

Authors:  Kelsey Jensen; David Jasen WuWong; Sean Wong; Mieko Matsuyama; Shigemi Matsuyama
Journal:  Exp Biol Med (Maywood)       Date:  2019-03-05

4.  Protein and Antibody Engineering by Phage Display.

Authors:  J C Frei; J R Lai
Journal:  Methods Enzymol       Date:  2016-06-29       Impact factor: 1.600

5.  Interrogation of side chain biases for oligomannose recognition by antibody 2G12 via structure-guided phage display libraries.

Authors:  Tsung-Yi Lin; Jonathan R Lai
Journal:  Bioorg Med Chem       Date:  2017-09-15       Impact factor: 3.641

6.  Lyciumamide A, a dimer of phenolic amide, protects against NMDA-induced neurotoxicity and potential mechanisms in vitro.

Authors:  Kai Gao; Meiyou Liu; Yuan Li; Lei Wang; Chao Zhao; Xian Zhao; Jinyi Zhao; Yi Ding; Haifeng Tang; Yanyan Jia; Jingwen Wang; Aidong Wen
Journal:  J Mol Histol       Date:  2021-03-23       Impact factor: 2.611

Review 7.  Physiological and pharmacological modulation of BAX.

Authors:  Adam Z Spitz; Evripidis Gavathiotis
Journal:  Trends Pharmacol Sci       Date:  2021-11-27       Impact factor: 14.819

8.  An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway.

Authors:  Thomas P Garner; Denis E Reyna; Amit Priyadarshi; Hui-Chen Chen; Sheng Li; Yang Wu; Yogesh Tengarai Ganesan; Vladimir N Malashkevich; Emily H Cheng; Evripidis Gavathiotis
Journal:  Mol Cell       Date:  2016-07-14       Impact factor: 17.970

9.  Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia.

Authors:  Denis E Reyna; Thomas P Garner; Andrea Lopez; Felix Kopp; Gaurav S Choudhary; Ashwin Sridharan; Swathi-Rao Narayanagari; Kelly Mitchell; Baoxia Dong; Boris A Bartholdy; Loren D Walensky; Amit Verma; Ulrich Steidl; Evripidis Gavathiotis
Journal:  Cancer Cell       Date:  2017-10-09       Impact factor: 31.743

10.  A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy.

Authors:  Dulguun Amgalan; Thomas P Garner; Ryan Pekson; Xiaotong F Jia; Mounica Yanamandala; Victor Paulino; Felix G Liang; J Jose Corbalan; Jaehoon Lee; Yun Chen; George S Karagiannis; Luis Rivera Sanchez; Huizhi Liang; Swathi-Rao Narayanagari; Kelly Mitchell; Andrea Lopez; Victoria Margulets; Marco Scarlata; Gaetano Santulli; Aarti Asnani; Randall T Peterson; Rachel B Hazan; John S Condeelis; Maja H Oktay; Ulrich Steidl; Lorrie A Kirshenbaum; Evripidis Gavathiotis; Richard N Kitsis
Journal:  Nat Cancer       Date:  2020-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.